“Following receipt of TGA SAS approval, physicians who have been informed by the Company on the use of Zilosul® may now prescribe Zilosul® to patients with persistent pain and loss of joint function due to arthralgia associated with RRV, patients who have previously received, tolerated, and benefited from the Zilosul® treatment under SAS and other patients who do not qualify for recruitment into the Para_OA_008 or Para_OA_002 clinical trials. ”
given how specific the trial acceptance criteria are many people won’t qualify so would have access through SAS
“Following receipt of TGA SAS approval, physicians who have been...
Add PAR (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
25.0¢ |
Change
-0.005(1.96%) |
Mkt cap ! $87.44M | |||
| Open | High | Low | Value | Volume |
| 25.0¢ | 26.5¢ | 25.0¢ | $71.50K | 278.2K |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 3 | 72166 | 25.0¢ |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| 26.0¢ | 1950 | 1 |
View Market Depth
| Last trade - 16.10pm 08/05/2024 (20 minute delay) ? |
|
|||||
|
Last
25.5¢ |
Change
-0.005 ( 2.00 %) |
||||
| Open | High | Low | Volume | ||
| 26.0¢ | 26.5¢ | 25.0¢ | 110340 | ||
| Last updated 15.56pm 08/05/2024 ? | |||||
| PAR (ASX) Chart |